365651322023041120250801
2214-36021022023Journal of neuromuscular diseasesJ Neuromuscul DisDystrophin Genotype and Risk of Neuropsychiatric Disorders in Dystrophinopathies: A Systematic Review and Meta-Analysis.159172159-17210.3233/JND-221586Dystrophinopathies are associated with neuropsychiatric disorders due to alterations in dystrophin/DMD expression.The objective was to estimate the association of developmental disorders, autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder with the dystrophin/DMD genotype in population with dystrophinopathies.Systematic searches of Medline, Scopus, Web of Science, and Cochrane Library were performed from inception to September 2022. We included observational studies in the population with Becker or Duchenne muscular dystrophies (BMD, DMD) that estimated the prevalence of these disorders according to Dp140 and/or Dp71 genotype. Meta-analysis of the prevalence ratio (PR) of genotype comparisons was conducted for each disorder.Ten studies were included in the systematic review. In BMD, Dp140+ vs. Dp140- and Dp71+ vs. Dp71- were associated with developmental disorders with a PR of 0.11 (0.04, 0.34) and 0.22 (0.07, 0.67), respectively. In DMD, Dp140+/Dp71+ vs. Dp140- /Dp71- had a PR of 0.40 (0.28, 0.57), and Dp71+ vs. Dp71- had a PR of 0.47 (0.36, 0.63) for ADHD. However, there was no association of genotype with ASD, only a trend was observed for Dp71+ vs. Dp71-, with a PR of 0.61 (0.35, 1.06). Moreover, the data showed no association of these isoforms with emotional-related disorders.In BMD, Dp140 and Dp71 could be associated with developmental disorders, while ADHD might be associated with the Dp71 genotype in DMD. Further research is needed regarding Dp140 and Dp71, especially in DMD for ASD.Pascual-MorenaCarlosCHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.Cavero-RedondoIvánIHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.Facultadde Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile.Martínez-VizcaínoVicenteVHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.Facultadde Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile.Sequí-DomínguezIreneIHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.Fernández-Bravo-RodrigoJaimeJHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.Pharmacy Service. Hospital Virgen de laLuz, Cuenca, Spain.Jiménez-LópezEstelaEHealth and Social Research Center, Universidad deCastilla- La Mancha, Cuenca, Spain.engMeta-AnalysisSystematic ReviewJournal Article
United StatesJ Neuromuscul Dis1016499482214-35990140-kDa dystrophin0apo-dystrophin 10DystrophinIMHumansDystrophingeneticsGenetic Predisposition to DiseasegeneticsGenotypeMental DisordersepidemiologygeneticspsychologyMuscular DystrophiesepidemiologygeneticspsychologyMuscular Dystrophy, DuchenneepidemiologygeneticspsychologyPrevalenceDuchenne muscular dystrophyDystrophinautistic disordermood disordersneurodevelopmental disordersThe authors declare no conflicts of interest, and no funding was received for this study.2022122560202331560202212244232023327ppublish36565132PMC1004143110.3233/JND-221586JND221586 Holland A, Carberry S, Ohlendieck K. Proteomics of the Dystrophin-glycoprotein Complex and Dystrophinopathy. Curr Protein Pept Sci [Internet]. 2014[cited 2021 Apr 17];14(8):680–97. Available from: https://pubmed.ncbi.nlm.nih.gov/24106963/.24106963 Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol [Internet]. 2019[cited 2022 Mar 27];32(5):722–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31343429/.31343429Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet (London, England). 1991;337(8748):1022–4.1673177 Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord [Internet]. 2014[cited 2020 Mar 26];24(6):482–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24780148.24780148Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Vol. 17, The Lancet Neurology. Lancet Publishing Group; 2018, pp. 251–67.PMC586970429395989 Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part Respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol [Internet]. 2018[cited 2019 May 13];17(4):347–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29395990.PMC588909129395990 Pascual-Morena C, Cavero-Redondo C, Saz-Lara A, Sequí-Domínguez I, Lucerón-Lucas-Torres M, Martínez-Vizcaíno V. Genetic modifiers and phenotype of duchenne muscular dystrophy: A systematic review and meta-analysis. Pharmaceuticals (Basel) [Internet]. 2021[cited 2021 Nov 2];14(8). Available from: https://pubmed.ncbi.nlm.nih.gov/34451895/.PMC840162934451895 Goemans N. How glucocorticoids change life in Duchenne muscular dystrophy [Internet]. The Lancet. Lancet Publishing Group. 2018[cited 2021 Apr 17];391:406–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29174483/.29174483 Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Mesas AE, Pozuelo-Carrascosa D, Martínez-Vizcaíno V. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review. Ann Clin Transl Neurol [Internet]. 2020[cited 2020 Sep 19]; 7(9):acn3.51149. Available from:https://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.51149.10.1002/acn3.51149PMC748092233325654Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part Primary care, emergency management, psychosocial care, and transitions of care across the lifespan. LANCET Neurol. 2018;17(5):445–55.PMC590240829398641Sekiguchi M, Zushida K, Yoshida M, Maekawa M, Kamichi S, Yoshida M, et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain. 2009;132(Pt 1):124–35.18927146 Doorenweerd N. Combining genetics, neuropsychology and neuroimaging to improve understanding of brain involvement in Duchenne muscular dystrophy - a narrative review. Neuromuscul Disord [Internet]. 2020;30(6):437–42. Available from: https://pubmed.ncbi.nlm.nih.gov/32522501/.32522501Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T’ Hoen PAC, Hendriksen JGM, et al. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci Rep. 2017;7(1):12575.PMC562677928974727Daoud F, Candelario-Martínez A, Billard J-M, Avital A, Khelfaoui M, Rozenvald Y, et al. Role of mentalretardation-associated dystrophin-gene product Dp71 in excitatory synapse organization, synaptic plasticity and behavioral functions. PLoS One. 2009;4(8):e6574.PMC271870419649270Pascual-Morena C, Cavero-Redondo I, Reina-Gutiérrez S, Saz-Lara A, López-Gil JF, Martínez-Vizcaíno V. Prevalence of neuropsychiatric disorders in duchenne and becker musculardystrophies: A systematic review and meta-analysis. Arch Phys Med Rehabil. 2022.35839922 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. J Am Med Assoc [Internet]. 2000[cited 2021 Apr 17];283(15):2008–12. Available from: https://pubmed.ncbi.nlm.nih.gov/10789670/.10789670 Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series [Internet]. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. John Wiley and Sons; 2008. [cited 2020 Oct 28]; pp. 1–649. Available from: https://research.monash.edu/en/publications/cochrane-handbook-for-systematic-reviews-of-interventions-cochran. Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2022 Apr 17]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Neumann I, Pantoja T, Peñaloza B, Cifuentes L, Rada G. El sistema GRADE: Un cambio en la forma de evaluar la calidad de la evidencia y la fuerza de recomendaciones. Rev Med Chil [Internet]. 2014[cited 2022 Apr 28]; 142(5):630–5. Available from: https://pubmed.ncbi.nlm.nih.gov/25427021/.25427021 Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc [Internet]. 2015[cited 2020 Oct 1];13(3):196–207. Available from: https://pubmed.ncbi.nlm.nih.gov/26355603/.26355603DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.3802833 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med [Internet]. 2022[cited 2020 Nov 7];21(11):1539–58. Available from: https://pubmed.ncbi.nlm.nih.gov/12111919/.12111919 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj [Internet]. 1997[cited 2019 Dec 4];315(7109):629–34. Available from: https://pubmed.ncbi.nlm.nih.gov/9310563/.PMC21274539310563Lambert JT, Darmahkasih AJ, Horn PS, Rybalsky I, Shellenbarger KC, Tian C, et al. Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy. Muscle Nerve. 2020;61(2):156–62.31650559Mori-Yoshimura M, Mizuno Y, Yoshida S, Minami N, Yonemoto N, Takeuchi F, et al. Social involvement issues in patients with Becker muscular dystrophy: A questionnaire survey of subjects from a patient registry. Brain Dev. 2018;40(4):268–77.29196072Mori-Yoshimura M, Mizuno Y, Yoshida S, Ishihara N, Minami N, Morimoto E, et al. Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy. Neuromuscul Disord. 2019;29(12):930–9.31708335Colombo P, Nobile M, Tesei A, Civati F, Gandossini S, Mani E, et al. Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2017;21(4):639–47.28392227 Darmahkasih AJ, Rybalsky I, Tian C, Shellenbarger KC, Horn PS, Lambert JT, et al. Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy. Muscle and Nerve [Internet]. 2020;61(4):466–74. Available from: https://pubmed.ncbi.nlm.nih.gov/31909820/.31909820Pane M, Lombardo ME, Alfieri P, D’Amico A, Bianco F, Vasco G, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: Phenotype-genotype correlation. J Pediatr. 2012;161(4):705–9.e1.22560791Ricotti V, Mandy WPL, Scoto M, Pane M, Deconinck N, Messina S, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016;58(1):77–84.26365034Saito Y, Takeshita E, Komaki H, Nishino I, Sasaki M. Determining neurodevelopmental manifestations in Duchenne muscular dystrophy using a battery of brief tests. J Neurol Sci. 2022;440:120340.35849899Thangarajh M, Hendriksen J, McDermott MP, Martens W, Hart KA, Griggs RC, et al. Relationships between DMD mutations and neurodevelopment in dystrophinopathy. Neurology. 2019;93(17):e1597–604.PMC694646631594858Fujino H, Saito T, Matsumura T, Shibata S, Iwata Y, Fujimura H, et al. Autism spectrum disorders are prevalent among patients with dystrophinopathies. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2018;39(7):1279–82.29594829 Graus-Porta D, Blaess S, Senften M, Littlewood-Evans A, Damsky C, Huang Z, et al. Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron [Internet]. 2001[cited 2021 Nov 4];31(3):367–79. Available from: https://pubmed.ncbi.nlm.nih.gov/11516395/.11516395Ash A, Machado L, Raleigh SM, Anthony K. Neuropathophysiology of Duchenne muscular dystrophy: Involvement of the dystrophin isoform Dp71 in cell migration and proliferation. Neuromuscul Disord. 2018;28:S13–4. Reiner O, Karzbrun E, Kshirsagar A, Kaibuchi K. Regulation of neuronal migration, an emerging topic in autism spectrum disorders. J Neurochem [Internet]. 2016[cited 2021 Nov 4];136(3):440–56. Available from: https://pubmed.ncbi.nlm.nih.gov/26485324/.26485324Jagadha V, Becker LE. Brain morphology in Duchenne muscular dystrophy: A Golgi study. Pediatr Neurol. 1988;4(2):87–92.3242516 Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology [Internet]. 2009[cited 2021 Nov 4];57(7– 8):579–89. Available from: https://pubmed.ncbi.nlm.nih.gov/19627998/.19627998 Grillner P, Mercuri NB. Intrinsic membrane properties and synapticinputs regulating the firing activity of the dopamine neurons. BehavBrain Res [Internet]. 2002[cited 2021 Nov 4];130(1– 2):149–69. Available from: https://pubmed.ncbi.nlm.nih.gov/11864731/.11864731Bruchhage MMK, Bucci M-P, Becker EBE. Cerebellar involvement in autism and ADHD. Handb Clin Neurol. 2018;155:61–72.29891077 Vaillend C, Chaussenot R. Relationships linking emotional, motor, cognitive and GABAergic dysfunctions in dystrophin-deficient mdx mice. Hum Mol Genet [Internet]. 2017[cited 2021 Nov 4];26(6):1041–55. Available from: https://pubmed.ncbi.nlm.nih.gov/28087735/.28087735Domschke K, Lawford B, Young R, Voisey J, Morris CP, Roehrs T, et al. Dysbindin (DTNBP1) - A role in psychotic depression? J Psychiatr Res. 2011;45(5):588–95.20951386Latimer R, Street N, Conway KC, James K, Cunniff C, Oleszek J, et al. Secondary conditions among males with duchenne or becker muscular dystrophy. J Child Neurol. 2017;32(7):663–70.PMC550275628393671Brown ES, Vera E, Frol AB, Woolston DJ, Johnson B. Effects of chronic prednisone therapy on mood and memory. J Affect Disord. 2007;99(1–3):279–83.PMC185252017030063Taylor PJ, Betts GA, Maroulis S, Gilissen C, Pedersen RL, Mowat DR, et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS One. 2010;5(1):e8803.PMC280835920098710